Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025

Reuters

Nov 04

Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025

Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580210133"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580210133\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580210133?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 00:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580210133","market":"nz","top_or_hot":-1,"title":"Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 00:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9Z6n4R:1","article_id":"2580210133","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580210133","pubTimestamp":1762185918,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology  Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI , a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","01548":"金斯瑞生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1583":"高瓴概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4505":"高瓴资本持仓","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","LEGN":"传奇生物","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"传奇生物在ASH 2025上公布新的CAR-T和同种异体细胞治疗数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":0.9,"LEGN":0.9,"NDAQ":0.9},"content_text":"Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n    \n\n        Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}